A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Phase 2 Unknown 100 enrolled Shanghai Miracogen Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-mutated unresectable or metastatic non-small-cell lung cancer (NSCLC).

Timeline

Start: 2021-12
Primary completion: 2023-12
Completion: 2023-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TRASTUZUMAB VEDOTIN	Unknown	2.6 mg/kg	Intravenous

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Summary

Timeline

Drugs

Indications